These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

834 related articles for article (PubMed ID: 33414138)

  • 1. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
    Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory/Active T-Cell Activation Is Associated with Immunotherapeutic Response in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Chen J; Hu X; Zhao J; Yin X; Zheng L; Guo J; Chen J; Wang Y; Sheng X; Dong H; Liu X; Zhang X; Liang J; Liu H; Yao J; Liu J; Shen Y; Chen Z; He Z; Wang Y; Chen N; Nie L; Zhang M; Pan X; Chen Y; Liu H; Zhang Y; Tang Y; Zhu S; Zhao J; Dai J; Wang Z; Zeng Y; Wang Z; Huang H; Liu Z; Shen P; Zeng H; Sun G
    Clin Cancer Res; 2024 Jun; 30(11):2571-2581. PubMed ID: 38512114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Rare Case of Synchronous Fumarate Hydratase-Deficient Renal Cell Carcinoma and Clear Cell Renal Cell Carcinoma With Fumarate Hydratase and von Hippel-Lindau Gene Mutations: A Clinicopathologic and Molecular Study.
    Wen H; Zheng L; Zhang M; Pan X; Wang D; Qian J; Zhang X; Zhou Q; Chen N
    Int J Surg Pathol; 2024 Jun; 32(4):810-816. PubMed ID: 37715637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
    Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
    Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic and transcriptomic features between primary and paired metastatic fumarate hydratase-deficient renal cell carcinoma.
    Liang J; Sun G; Pan X; Zhang M; Shen P; Zhu S; Zhao J; Zheng L; Zhao J; Chen Y; Yin X; Chen J; Hu X; Zeng Y; Chen J; Wang Y; Liu Z; Yao J; Su M; Huang R; Liao B; Wei Q; Li X; Zhou Q; Liu J; Shen Y; Liu Z; Chen N; Zeng H; Zhang X
    Genome Med; 2023 May; 15(1):31. PubMed ID: 37131267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Clinicopathologic and Molecular Analysis of Fumarate Hydratase-deficient Renal Cell Carcinoma in 32 Patients.
    Lau HD; Chan E; Fan AC; Kunder CA; Williamson SR; Zhou M; Idrees MT; Maclean FM; Gill AJ; Kao CS
    Am J Surg Pathol; 2020 Jan; 44(1):98-110. PubMed ID: 31524643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
    Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
    Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological characteristics of fumarate hydratase-deficient renal cell carcinoma].
    Zhang W; Chu J; Zou YW; Jiang YX; Wei ZM; Zhong DC; Liu Y; Li YJ; Yu WJ
    Zhonghua Bing Li Xue Za Zhi; 2019 Feb; 48(2):120-126. PubMed ID: 30695864
    [No Abstract]   [Full Text] [Related]  

  • 10. Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
    Shyu I; Mirsadraei L; Wang X; Robila V; Mehra R; McHugh JB; Chen YB; Udager AM; Gill AJ; Cheng L; Amin MB; Lin O; Smith SC
    Cancer Cytopathol; 2018 Dec; 126(12):992-1002. PubMed ID: 30339328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
    Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fumaratehydratase-deficient renal cell carcinoma: a clinicopathological and molecular study of 13 cases.
    Pan X; Zhang M; Yao J; Zeng H; Nie L; Gong J; Chen X; Xu M; Zhou Q; Chen N
    J Clin Pathol; 2019 Nov; 72(11):748-754. PubMed ID: 31262952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
    Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
    Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fumarate Hydratase-deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome.
    Trpkov K; Hes O; Agaimy A; Bonert M; Martinek P; Magi-Galluzzi C; Kristiansen G; Lüders C; Nesi G; Compérat E; Sibony M; Berney DM; Mehra R; Brimo F; Hartmann A; Husain A; Frizzell N; Hills K; Maclean F; Srinivasan B; Gill AJ
    Am J Surg Pathol; 2016 Jul; 40(7):865-75. PubMed ID: 26900816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fumarate hydratase-deficient renal cell carcinoma: an oncology care institutional experience.
    Kamboj M; Gupta G; Pasricha S; Mehta A; Rawal S; Singh A; Sharma A; Durga G; Bansal D; Diwan H
    APMIS; 2024 Aug; 132(8):544-552. PubMed ID: 38775301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
    Howells E; Wigston L; Mackie G; Tran B; Nott L
    Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fumarate hydratase-deficient renal cell carcinoma: A clinicopathological study of seven cases including hereditary and sporadic forms.
    Kuroda N; Tsutsui M; Iguchi M; Nobuoka E; Uehara T; Sonobe Y; Morinaga Y; Shibuya S; Oda W; Yanai H; Kawada C; Karashima T; Yamasaki I; Inoue K; Nagashima Y
    Ann Diagn Pathol; 2020 Dec; 49():151599. PubMed ID: 32977234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma].
    Yu YF; He SM; Wu YC; Xiong SW; Shen Q; Li YY; Yang F; He Q; Li XS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 53(4):640-646. PubMed ID: 34393221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Metastatic Fumarate Hydratase-Deficient-like Renal Cell Carcinoma Successfully Managed by Ipilimumab plus Nivolumab.
    Sekito T; Takamoto A; Kobayashi Y; Mitsui M; Watari S; Kubota R; Sadahira T; Iwata T; Nishimura S; Edamura K; Sako T; Araki M; Watanabe M; Watanabe T; Shibata R; Ennishi D; Nasu Y
    Acta Med Okayama; 2021 Jun; 75(3):397-402. PubMed ID: 34176946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma.
    Carril-Ajuria L; Colomba E; Cerbone L; Romero-Ferreiro C; Crouzet L; Laguerre B; Thibault C; Vicier C; de Velasco G; Fléchon A; Saldana C; Benusiglio PR; Bressac-de Paillerets B; Guillaud-Bataille M; Gaignard P; Scoazec JY; Richard S; Caron O; Escudier B; Albiges L
    Eur J Cancer; 2021 Jul; 151():106-114. PubMed ID: 33975058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.